REPLACEMENT: Final Results

AI SummaryClose X

Fusion Antibodies PLC has announced its final results for the year ended March 31, 2026, reporting audited revenues of £2.1 million, an increase from £1.97 million in the prior year, with gross margin significantly improving to 58.3% from 22%. The company also reported an improved operating loss of £1.13 million compared to a restated £1.63 million loss in the previous year, despite increased R&D investment. Other operating revenue of £872,000 was recognised, primarily from a grant program, and cash at year-end stood at £1.04 million, up from £0.36 million. The company also raised approximately £1.4 million in January 2026 to support its OptiMAL® commercialisation and working capital.

Disclaimer*

UK 100

Latest directors dealings